【ChiCTR1900026245】The role of extended antral resection on weight loss and metabolic response after sleeve gastrectomy: a retrospective cohort study
ChiCTR1900026245
结束
/
/
/
2019-09-28
/
/
obesity surgery
The role of extended antral resection on weight loss and metabolic response after sleeve gastrectomy: a retrospective cohort study
The role of extended antral resection on weight loss and metabolic response after sleeve gastrectomy: a retrospective cohort study
41900
LSG was initially designed as the first step of a two-staged bariatric procedure. However, in the following years, LSG was found as effective as other bariatric procedures and has become increasingly popular as a stand-alone bariatric procedure [1,2]. Recently, LSG is the most performed bariatric procedure worldwide [3]. The simplicity of surgical technique, preservation of the pyloric functions, none development of marginal ulcers or internal herniation, less need of trace element and vitamin supplementation are the advantages of LSG over other bariatric procedures [4-6]. However, debate continues regarding the AR or AP on effective weight loss alterations and metabolic response. Further, the distance from pylorus at which the stomach division should be started is still not standardized and has been reported varying from 2 to 8cm [7-9]. The aim of the present retrospective cohort study was to determine whether AR is superior to AP regarding weight loss and resolution of co-morbidities.
队列研究
回顾性研究
N/A
N/A
not funding
/
68;43
/
2016-01-01
2018-06-30
/
Patients with BMI > 40 were included.；
请登录查看Patients with a history of previous bariatric surgery and patients who did not attend regular follow-up visits (first, 6th and 12 month) are excluded.；
请登录查看not sponsored
41900
not sponsored的其他临床试验
土耳其安卡拉科卡埃利·德里斯培训和研究医院的其他临床试验
最新临床资讯
-
飞眸医疗首例人体临床试验（FIH）成功开展，国产飞秒屈光设备竞逐540亿屈光市场
动脉网-最新2026-09-10
-
和铂医药：超长效靶向TSLP抗体哮喘二期临床取得阳性结果，三期临床已启动
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
动脉网-最新2026-09-09
-
药明康德2026-09-09
-
一度医药2026-09-08
-
阿斯利康中国2026-09-08
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-09-26
-
2026-09-26
-
2026-09-26
-
摩熵咨询 20 8
-
摩熵咨询 20 11
-
摩熵咨询 34 56
-
颁布机构：国家药品监督管理局 2026-09-10
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-09-28
-
2026-09-26
-
2026-09-26
-
摩熵咨询 35 71
-
摩熵咨询 28 60
-
摩熵咨询 34 42
-
颁布机构：国家市场监督管理总局 2026-09-18
-
颁布机构：国家市场监督管理总局 2026-09-17
-
颁布机构：国家市场监督管理总局 2026-08-10